190 related articles for article (PubMed ID: 15968953)
1. Quotidian nocturnal hemodialysis improves cytokine profile and enhances erythropoietin responsiveness.
Yuen D; Richardson RM; Fenton SS; McGrath-Chong ME; Chan CT
ASAIO J; 2005; 51(3):236-41. PubMed ID: 15968953
[TBL] [Abstract][Full Text] [Related]
2. Impact of nocturnal home hemodialysis on anemia management in patients with end-stage renal disease.
Schwartz DI; Pierratos A; Richardson RM; Fenton SS; Chan CT
Clin Nephrol; 2005 Mar; 63(3):202-8. PubMed ID: 15786821
[TBL] [Abstract][Full Text] [Related]
3. Nocturnal hemodialysis improves erythropoietin responsiveness and growth of hematopoietic stem cells.
Chan CT; Liu PP; Arab S; Jamal N; Messner HA
J Am Soc Nephrol; 2009 Mar; 20(3):665-71. PubMed ID: 19092123
[TBL] [Abstract][Full Text] [Related]
4. Role of cytokines in the response to erythropoietin in hemodialysis patients.
Goicoechea M; Martin J; de Sequera P; Quiroga JA; Ortiz A; Carreño V; Caramelo C
Kidney Int; 1998 Oct; 54(4):1337-43. PubMed ID: 9767553
[TBL] [Abstract][Full Text] [Related]
5. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients.
Kalantar-Zadeh K; McAllister CJ; Lehn RS; Lee GH; Nissenson AR; Kopple JD
Am J Kidney Dis; 2003 Oct; 42(4):761-73. PubMed ID: 14520627
[TBL] [Abstract][Full Text] [Related]
6. Relationship between insulin resistance and erythropoietin responsiveness in hemodialysis patients.
Abe M; Okada K; Soma M; Matsumoto K
Clin Nephrol; 2011 Jan; 75(1):49-58. PubMed ID: 21176750
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human erythropoietin resistance in hemodialysis. Effects of paired filtration dialysis.
Carozzi S; Nasini MG; Santoni O; Tirotta A; Sanna A
ASAIO J; 1997; 43(5):M535-8. PubMed ID: 9360100
[TBL] [Abstract][Full Text] [Related]
8. Relationship between erythropoietin responsiveness, insulin resistance, and malnutrition-inflammation-atherosclerosis (MIA) syndrome in hemodialysis patients with diabetes.
Abe M; Okada K; Maruyama T; Maruyama N; Matsumoto K; Soma M
Int J Artif Organs; 2011 Jan; 34(1):16-25. PubMed ID: 21298620
[TBL] [Abstract][Full Text] [Related]
9. Factors related to erythropoietin hypo-responsiveness in patients on chronic peritoneal dialysis.
Wei M; Bargman JM; Oreopoulos DG
Int Urol Nephrol; 2007; 39(3):935-40. PubMed ID: 17534732
[TBL] [Abstract][Full Text] [Related]
10. The use of nocturnal home hemodialysis as salvage therapy for patients experiencing peritoneal dialysis failure.
Wong JH; Pierratos A; Oreopoulos DG; Mohammad R; Benjamin-Wong F; Chan CT
Perit Dial Int; 2007; 27(6):669-74. PubMed ID: 17984429
[TBL] [Abstract][Full Text] [Related]
11. Serum-soluble Fas and serum levels of erythropoietin in chronic kidney disease.
Góes MA; Dalboni MA; Manfredi SR; Cendoroglo MS; Batista MC; Canziani ME; Balakrishnan VS; Pereira BJ; Draibe SA; Cendoroglo M
Clin Nephrol; 2010 Jan; 73(1):7-13. PubMed ID: 20040346
[TBL] [Abstract][Full Text] [Related]
12. Management of anemia with quotidian hemodialysis.
Rao M; Muirhead N; Klarenbach S; Moist L; Lindsay RM
Am J Kidney Dis; 2003 Jul; 42(1 Suppl):18-23. PubMed ID: 12830439
[TBL] [Abstract][Full Text] [Related]
13. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis.
Coronel F; Herrero JA; Montenegro J; Fernandez C; Gandara A; Conesa J; Rivera MT; Torrente J; Portolés J; Gomez-Martino JR
J Nephrol; 2003; 16(5):697-702. PubMed ID: 14733416
[TBL] [Abstract][Full Text] [Related]
14. Erythropoietin requirements increase following hospitalization in end-stage renal disease patients.
Yaqub MS; Leiser J; Molitoris BA
Am J Nephrol; 2001; 21(5):390-6. PubMed ID: 11684801
[TBL] [Abstract][Full Text] [Related]
15. Improved parathyroid hormone control by cinacalcet is associated with reduction in darbepoetin requirement in patients with end-stage renal disease.
Battistella M; Richardson RM; Bargman JM; Chan CT
Clin Nephrol; 2011 Aug; 76(2):99-103. PubMed ID: 21762640
[TBL] [Abstract][Full Text] [Related]
16. Erythropoietin requirement in patients with type 2 diabetes mellitus on maintenance hemodialysis therapy.
Biesenbach G; Schmekal B; Eichbauer-Sturm G; Janko O
Wien Klin Wochenschr; 2004 Dec; 116(24):844-8. PubMed ID: 15690969
[TBL] [Abstract][Full Text] [Related]
17. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
18. Response to erythropoietin in pediatric patients with chronic kidney disease: insights from an in vitro bioassay.
Gavish R; Watad S; Ben-Califa N; Goldberg OJ; Haskin O; Davidovits M; Koren G; Falush Y; Neumann D; Krause I
Pediatr Nephrol; 2018 Nov; 33(11):2123-2129. PubMed ID: 30030607
[TBL] [Abstract][Full Text] [Related]
19. [Erythropoietin-beta in the treatment of anemia in patients with chronic renal insufficiency].
Dimković N
Med Pregl; 2001; 54(5-6):235-40. PubMed ID: 11759218
[TBL] [Abstract][Full Text] [Related]
20. Reduction in cardiovascular related hospitalization with nocturnal home hemodialysis.
Bergman A; Fenton SS; Richardson RM; Chan CT
Clin Nephrol; 2008 Jan; 69(1):33-9. PubMed ID: 18218314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
